Parkinson's disease

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Mittwoch, März 6, 2024
TMS, Parkinson's disease, Medicine, Mental health, Human, Traction, Growth, Stroke, Adjustment, Safety, DSM-IV codes, Tic disorder, Mixed anxiety–depressive disorder, Brainsway, Journal, Rehabilitation, Science, OCD, Transcranial magnetic stimulation

BURLINGTON, Mass. and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.

Key Points: 
  • and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.
  • Gross margin for the fourth quarter of 2023 was 75%, an increase from 71% in the fourth quarter of 2022, and an increase from 74% in the third quarter of 2023.
  • Net income for the fourth quarter of 2023 was $0.1 million, compared to a net loss of $3.9 million for the fourth quarter of 2022, and a loss of $0.2 million for the third quarter of 2023.
  • Adjusted EBITDA1 for the fourth quarter of 2023 was approximately $0.8 million, compared to a loss of $3.6 million for the fourth quarter of 2022, and positive Adjusted EBITDA1 of $0.3 million in the third quarter of 2023.

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Freitag, März 1, 2024
L-DOPA, MCP1, Chemokine, Alzheimer's disease, Phagocytosis, Political moderate, Principal, MDS-UPDRS, Cholesterol, Insulin, Inflammation, Part, ADAS, Plaque, Conference, Placebo-controlled study, Parkinson's disease, Diabetes, Carbidopa/levodopa, Pharmacokinetics, Digestion, Disease, DNA methylation, DNA, Brain, Pharmaceutical industry

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Retrieved on: 
Mittwoch, Februar 28, 2024
Therapy, Division, Blood, Mesylate, FDA, Physician, Bone marrow, Food, Approximation error, Risk, Imatinib, Parkinson's disease, Patient, Trial of the century, NDA

“With the full meeting minutes from the FDA Review Team in hand, we are confident in our approach as we develop the NDA for IkT-001Pro,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.

Key Points: 
  • “With the full meeting minutes from the FDA Review Team in hand, we are confident in our approach as we develop the NDA for IkT-001Pro,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • Further, we are not restricted from use in children nor restricted to just blood cancer-related approved indications.
  • This opens-up the opportunity to seek all 11 approved indications for IkT-001Pro that were previously approved for imatinib mesylate.
  • All other elements of the pre-NDA meeting remain unchanged from those reported on February 7, 2024.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Dienstag, Februar 27, 2024
Master of Science, PD, Doctor of Philosophy, Medical school, GBA, Alpha-synuclein, Conference, EMBA, Parkinson's disease, Medical University of Innsbruck, Biomarker, Mayo Clinic, Multiple system atrophy, Patient, Dementia, Synucleinopathy, Development, DSM-IV codes, Lewy body, Biogen, Management

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Freitag, Februar 23, 2024
Emotion, Neuroscience, Journal of Neuroscience Research, Neuron, Amnesia, Growth, Swelling, TBI, Perception, Attention, Mammal, Circadian rhythm, Diagnosis, PBM, Sunlight, Head, Traumatic brain injury, Stroke, DSM-IV codes, Memory, Light, Immunity, Brain, Anxiety, Randomized controlled trial, Sleep, Radical, Learning, Parkinson's disease, RLT, Oxidative stress, Glucose, Potential, LLLT, Research, Human, LED, BBA, System, Dicarboxylic acid, Inflammation, Neuroprotection, FDA, Sensation, Ageing, Thought, Cell, Brain damage, Nutrient, Patient, Cognition, Dementia, Antioxidant, Medical imaging

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Donnerstag, Februar 22, 2024
Retinitis pigmentosa, Liver, OTCQB, Cancer, Cataract, Alzheimer's disease, MD, Inflammation, Retina, Systemic disease, Patent, Swelling, Huntington's disease, Eye, Geography, Optical flow, Disease, Connective tissue, Biomarker, Anatomy, Kidney disease, Emaciation, Heart, Diagnosis, Conformation, Risk, Atrophy, Element, Cystic fibrosis, Parkinson's disease, Brain, Medical imaging

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Mittwoch, März 6, 2024
Health, Genetics, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Liver, Parkinson's disease, Pet, Movement disorder, Annual report, Marketing, Investment, WalletHub, ChromaDex, Growth, Conference, Biomarker, GAAP, Tru, Replay, History, NAD, Infant, Patient, Optimism, Webcast, Clinical trial, Security (finance), Nature Communications, Longevity, Heart, Brain, Research, Partnership, Pharmaceutical industry

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
  • Maintained positive operating cash flows for a fourth consecutive quarter, ending with $27.3 million in cash and no debt.
  • Additionally, the fourth quarter marked an important milestone with the company achieving positive net income,” said Rob Fried, ChromaDex Chief Executive Officer.
  • ChromaDex ended fiscal year 2023 with $27.3 million in cash and cash equivalents and no debt.

S.BIOMEDICS completes brain transplant of hESC-derived dopaminergic progenitors (TED-A9) for Phase 1/2a study in patients with Parkinson’s disease

Retrieved on: 
Donnerstag, Februar 29, 2024
Stem Cells, Data Management, Biotechnology, Technology, Health, Neurology, Research, Hospitals, Surgery, Science, Clinical Trials, Severance Hospital, Dyskinesia, KOSDAQ, Safety, Neuron, Yonsei University, DLT, Freezing, Cell, Parkinson's disease, Transplant, Putamen, Patient, Clinical trial, Gait, Brain, Pharmaceutical industry

S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.

Key Points: 
  • S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.
  • The primary objective of the Phase 1/2a trial is to assess the safety and exploratory efficacy of TED-A9 transplantation for two years post-transplant.
  • “We have developed a fundamental therapeutic mechanism that directly replaces dopaminergic neurons lost in patients with Parkinson's disease.
  • TED-A9 could represent a fundamental treatment that surpasses current therapies, which only temporarily alleviate the symptoms of Parkinson’s disease,” he added.

Introducing Unlearn’s TrialPioneer: A Free Tool for Exploring Innovative Clinical Trial Designs Using AI

Retrieved on: 
Donnerstag, Februar 29, 2024
Software, General Health, Pharmaceutical, Data Management, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Biotechnology, Other Technology, Health, Parkinson's disease, ALS, Frontotemporal dementia, AI, Food, Drug development, Stroke, Disease, European Medicines Agency, Patient, Clinical trial, Probability, Clutch (eggs), Research, Pharmaceutical industry

It also reveals the major advantages that novel AI-powered trial designs offer over traditional approaches.

Key Points: 
  • It also reveals the major advantages that novel AI-powered trial designs offer over traditional approaches.
  • TrialPioneer is designed to make clinical trial planning more efficient for professionals, including medical directors, clinicians, and statisticians.
  • It also illustrates how innovative trial designs, such as Unlearn’s TwinRCTs TM, can improve these metrics.
  • With TrialPioneer, we’re offering a free, powerful, and easy-to-use tool that enables anyone from any background to explore trial planning in a simple way, even with innovative trial designs that leverage tools like AI.

InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO

Retrieved on: 
Dienstag, Februar 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain

InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.

Key Points: 
  • InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
  • Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
  • ," says Véronique Foutel, CEO of InBrain Pharma.
  • "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.